Tours, 20-22 November 2012, Vinci Centre International de Congrès
Header

Programme

Télécharger:

Abstracts

Programme scientifique

20th November – Afternoon

13:00-14:00: Welcome

14:00-14:40: Opening ceremony

14:40-16:10: Anti-bacterial antibodies 

Chair :  Philippe Thullier/ Nathalie Heuzé-Vourc’h  

  • Development of a recombinant IgG neutralizing the anthrax lethal toxin Thibaut Pelat, Institut de Recherche Biomédicale des Armées, France

  • Development of Heavy chain antibodies against the Penton-Valentine leukocidine from S. aureus Dubravka Drabek, Erasmus Medical Center, Netherlands

  • Human Monoclonal Antibodies Against Staphylococcal Enterotoxin B:  Inhibitors of Toxic Shock Bradley G. Stiles, Wilson College, USA

16:10-17:00: Coffee break

17:00-18:30: Anti-viral antibodies (I)

Chair : Isabelle Dimier-Poisson / Denys Brand

  • Human mAbs against Hendra and Nipah viruses: from discovery in academic setting to administration in humans Dimiter S. Dimitrov, Frederick National Laboratory for Cancer Research, NIH, USA

  • Rewriting History: Antibody Therapeutics for Filoviruses John M. Dye, USAMRIID, USA

  • Isolation and Characterization of scFvs targeting Filoviruses Jeffrey W. Froude, USAMRMC, USA

21st November

08:00-08:30Welcome

08:30-10:30: Anti-microbial antibodies and effector functions

Chair : Dominique Buzoni- Gatel / Gilles Thibault

  • Development of panobacumab, anti- P. aeruginosa LPS serotype IATS O11 Antonio Perez, Kenta Biotech, Switzerland

  • IgG-FcgR binding and effector functions Pierre Bruhns, Institut Pasteur, France

  • An endogenous human antibody directed against a conserved epitope of M2 confers full protection against various Influenza A strains in an in vivo model system        Anton Bauer, Intercell, Austria

  • Vaccine-like effects of antiviral monoclonal antibodies  Mireia Pelegrin, IGMM, France

10:30-11:30: Coffee break

11:30-12:30Anti-viral antibodies (II) 

Chair : Francis Barin  / Stéphane Paul

  • Broadlly neutralizing antibodies present new prospects to counter HIV infection Pascal Poignard, The Scripps Research Institut, USA

  • Nanobodies based on a dromadary single-domain antibody targeting HIV-1 reverse transcriptase Naima Abidi-Azzouz, Centre de Recherches de Biochimie Macromoléculaire, France


12:30-14:00Lunch

14:00-15:30: Anti-viral antibodies (III)

Chair : Philippe Roingeard / Valérie Gouilleux-Gruart

  • From polyclonal immunoglobulin to monoclonal antibody: an urgent need for rabies post-exposure prophylaxis Laurent Dacheux, Institut Pasteur, France

  • Broadly neutralizing alpaca nanobody blocks virus entry and cell-cell transmission of Hepatitis C Virus Pierre Lafaye , Institut Pasteur, France

  • Targeting host entry factors for prevention and treatment of hepatitis C virus infection Mirjam Zeisel, University of Strasbourg, France


15:30-16:30: Keynote lecture

Chair : Hervé Watier

  • Regulatory aspects in the development of monoclonal antibody cocktails  Patrick G. Swann, Office of Biotechnology Products, FDA, USA


16:30-17:00Coffee break

17:00-18:30Involvement of the French biotech industry in the field

Chairman: Jean-Luc Teillaud

  • Development of anti-Shiga toxin mAbs Christian Behrens, LFB Biotechnologies, France

  • The ISAAC and VIVA SCREEN platforms for the generation of human mAbs Majid Mehtali, Vivalis, France

  • Monoclonal antibodies against infectious diseases at Sanofi : where are we?  Laurent Fraisse, SANOFI, France

20:00 : Gala dinner

 

22nd November – Morning

08:30-09:00Welcome

09:00-12:00Therapeutic antibodies and infectious diseases: a double edge sword?

Chair: Yvon Lebranchu/ Théodora Angoulvant

  • Eculizumab in severe Shiga toxin-associated hemolytic and uremic syndromes (STEC-HUS)  Christian Combe, University of Bordeaux Segalen, France

  • Rituximab in mixed cryoglobulinemia secondary to hepatitis C virus infection Marcella Visentini, Sapienza University of Rome, Italy

  • Tuberculosis and other opportunistic infections during anti-TNF therapy, the French RATIO registry Xavier Mariette, University of Paris-Sud  11, France

  • Natalizumab-associated progressive multifocal leukoencephalopathy (PML) Patrick Vermersch, University  of Lille Nord , France

  • CTLA4-Ig and risk of lymphoproliferation after EBV primo-infection Bernard Charpentier, University of Paris-Sud  11, France


12:00Lunch

14:00: End of Congress